Trial Profile

A Randomised, Placebo-controlled, Double-blind, Repeat Dose Escalation Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omipalisib (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Pharmacodynamics; Pharmacokinetics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

14 Feb 2019 Results evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of omipalisib in subjects Idiopathic Pulmonary Fibrosis published in the European Respiratory Journal
24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
16 Aug 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com